APA (7th ed.) Citation

Sharmin, S., Lefort, M., Andersen, J. B., Leray, E., Horakova, D., Havrdova, E. K., . . . Boz, C. (2021). Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 35(11), 1217. https://doi.org/10.1007/s40263-021-00860-7

Chicago Style (17th ed.) Citation

Sharmin, Sifat, et al. "Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts." CNS Drugs 35, no. 11 (2021): 1217. https://doi.org/10.1007/s40263-021-00860-7.

MLA (9th ed.) Citation

Sharmin, Sifat, et al. "Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts." CNS Drugs, vol. 35, no. 11, 2021, p. 1217, https://doi.org/10.1007/s40263-021-00860-7.